KBI BIOPHARMA
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 15 Jan 2025)
What this means for you
Registered since 20 Aug 2019. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88282125
- Registration number
- 5839075
- Mark type
- Design + words
- Filed
- 30 Jan 2019
- Published for opposition
- 04 Jun 2019
- Registered
- 20 Aug 2019
- Attorney of record
- F. Michael Sajovec
Goods and services
- Class 040 — Treatment of materials: contract manufacturing in the field of biopharmaceuticals
- Class 042 — Scientific and technological services: contract biopharmaceutical drug development services
Owner
- KBI Biopharma, Inc., Durham, NC, US
- KBI Biopharma, Inc., Durham, NC, US
- KBI Biopharma, Inc., Durham, NC, US
Prosecution history
- 15 Jan 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 15 Jan 2025 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 15 Jan 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 21 Aug 2024 — TEAS SECTION 8 & 15 RECEIVED
- 20 Aug 2024 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 20 Aug 2019 — REGISTERED-PRINCIPAL REGISTER
- 04 Jun 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 04 Jun 2019 — PUBLISHED FOR OPPOSITION
- 15 May 2019 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 30 Apr 2019 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 29 Apr 2019 — ASSIGNED TO LIE
- 16 Apr 2019 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 16 Apr 2019 — EXAMINER'S AMENDMENT ENTERED
- 16 Apr 2019 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 16 Apr 2019 — EXAMINERS AMENDMENT E-MAILED